U.S. FDA approves CAPVAXIVE (V116), specifically designed for pneumococcal disease in adults
Across four Phase 3 studies, CAPVAXIVE demonstrated robust immune responses in both vaccine-naïve and vaccine-experienced adult…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Pneumococcal disease
Merck gets US FDA nod of adult pneumococcal 15-valent conjugate vaccine
VAXNEUVANCE demonstrated non-inferior immune responses for the serotypes shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,…
Serum Institute of India launches indigenously developed pneumococcal vaccine,…
This WHO pre-qualified PCV is specially tailored to the prevailing serotype prevalence of S. pneumoniae in India and other regions…